<SEC-DOCUMENT>0000950103-24-007243.txt : 20240529
<SEC-HEADER>0000950103-24-007243.hdr.sgml : 20240529
<ACCEPTANCE-DATETIME>20240529160525
ACCESSION NUMBER:		0000950103-24-007243
CONFORMED SUBMISSION TYPE:	SD
PUBLIC DOCUMENT COUNT:		1
<RULE>
<RULE-NAME>13p-1
<ITEM>
<ITEM-NUMBER>1.01
<ITEM-PERIOD>20231231
</ITEM>
</RULE>
FILED AS OF DATE:		20240529
DATE AS OF CHANGE:		20240529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
		CENTRAL INDEX KEY:			0001100682
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				061397316
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		SD
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15943
		FILM NUMBER:		24998320

	BUSINESS ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887
		BUSINESS PHONE:		781-222-6000

	MAIL ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHARLES RIVER LABORATORIES INTERNATIONAL INC
		DATE OF NAME CHANGE:	20000605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHARLES RIVER LABORATORIES HOLDINGS INC
		DATE OF NAME CHANGE:	19991208
</SEC-HEADER>
<DOCUMENT>
<TYPE>SD
<SEQUENCE>1
<FILENAME>dp211739_sd.htm
<DESCRIPTION>FORM SD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15pt 0pt 7.9pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15pt 0pt 7.9pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 7.9pt; text-align: center"><B>FORM SD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 7.9pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 7.9pt; text-align: center">Specialized Disclosure Report</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 7.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15pt 0pt 7.9pt; text-align: center"><B>Charles River Laboratories International,
Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 7.9pt; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 7.9pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; font-weight: bold; text-align: center">State of Delaware</TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center">001-15943</TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center">06-1397316</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction</TD>
    <TD STYLE="text-align: center">(Commission</TD>
    <TD STYLE="text-align: center">(IRS Employer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">of incorporation or organization)</TD>
    <TD STYLE="text-align: center">File Number)</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; font-weight: bold; text-align: center">251 Ballardvale Street</TD>
    <TD STYLE="width: 49%; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Wilmington, Massachusetts</B></FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>01887</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 7.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 7.9pt; text-align: center">Matthew Daniel, (781) 222-6000</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 7.9pt; text-align: center"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Name and telephone number, including area code, of the
person to contact in connection with this report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 17.65pt">Check the appropriate box to indicate the rule pursuant
to which this form is being filed, and provide the period to which the information in this form applies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 17.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9745;</FONT></TD><TD>Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1)
for the reporting period from January 1 to December 31, 2023.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.65pt"></TD><TD STYLE="width: 15.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD><TD>Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 30, 2023.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Introduction</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">We are a leading, non-clinical global drug development
partner with a mission to create healthier lives. For over 75 years, we have been in the business of providing the research models required
in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency
of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment
services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development.
We also provide a suite of products and services to support our clients&rsquo; manufacturing activities. Utilizing our broad portfolio
of products and services enables our clients to create a more efficient and flexible drug development model, which reduces their costs,
enhances their productivity and effectiveness, and increases speed to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">Charles River is aware of the grave concerns and global
issues that stem from the commercialization of <I>Conflict Minerals</I> in the Democratic Republic of the Congo and its adjoining countries.
Thus, Charles River has been actively working with its business partners and others to promote responsible sourcing of <I>Conflict Minerals</I>
within its supply chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.1pt 0pt 5pt">In accordance with Rule 13p-1 (17 CFR 240.13p-1) under
the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the Rule), Charles River has conducted a Reasonable Country
of Origin Inquiry (RCOI) and related due diligence consistent with the Organization for Economic Co-operation and Development (OECD) Due
Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High Risk Areas, and the OECD Supplement on Tin,
Tantalum, and Tungsten (Second Edition, 2013) for its Endosafe Products (described below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.1pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">For purposes hereof, all <I>capitalized and italicized</I>
terms used herein and not otherwise defined shall have the meaning ascribed to such terms in the Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Caution Concerning Forward - Looking Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5pt">This Current Report on Form SD includes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by
the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
&ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;outlook,&rdquo; and &ldquo;project,&rdquo; and other similar expressions
that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based
on the Company's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated or implied by the forward-looking statements. For example, we may use
forward-looking statements when addressing topics such as: the steps we intend to take to mitigate the risk that our necessary <I>Conflict
Minerals</I> may benefit armed groups&#894; the implementation of satisfactory traceability and other compliance measures by our direct
and indirect suppliers, on a timely basis or at all&#894; whether smelters and refiners and other market participants responsibly source
<I>Conflict Minerals</I>, and political and regulatory developments, whether in the <I>Covered Countries</I>, the United States or elsewhere.
A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company's Annual
Report on Form 10-K as filed on February 14, 2024, as well as other filings the Company makes with the Securities and Exchange Commission.
Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events
currently expected by the Company, and the Company assumes no obligation and expressly disclaims any duty to update information contained
in this Form SD except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5pt">&nbsp;</P>



<P STYLE="margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Product Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 5pt">Charles River does not knowingly or intentionally procure
or otherwise source <I>Conflict Minerals</I> for any of its products that it manufactures or contracts to manufacture, except with regards
to its Endosafe Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">Charles River&rsquo;s Microbial Solutions business provides
<I>in vitro</I> methods for conventional and rapid quality control testing. In connection therewith, the Microbial Solutions division
contracts to manufacture for sale to third parties four (4) products (Endosafe&reg;-nexgen PTS&trade; Model PTS150 and Model PTS150nw
Portable Test Systems, Endosafe&reg;-MCS&trade; Multi-Cartridge System, and Endosafe&reg;-Nexus 200&trade; Automated Multi-Cartridge System&#894;
collectively the Endosafe Products) that contain electronic components, some of which include certain <I>Conflict Minerals</I> (tantalum
and tin) that are necessary for their functionality and/or production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 5pt">The Endosafe Products form a rapid, point-of-use test
system comprised of test cartridges and use of a spectrophotometer where certain assays can be executed (<I>e.g</I>., Gram ID, Inhibition/Enhancement
LAL, Glucan) and can determine if certain injectable therapeutics during the drug manufacturing and production processes are safe for
human use (<I>i.e</I>., whether such therapeutics are endotoxin-free). Tantalum is used in certain capacitors within the power circuitry
as it dramatically reduces the size of the capacitor and eliminates chemical disposal issues&#894; and tin is used to solder electronics
components on printed circuit boards consistent with industry practice due to its reliable performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">SECTION 1 - CONFLICT MINERALS DISCLOSURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><B>Item 1.01 Conflict Minerals Disclosure and Report Reasonable
Country of Origin Inquiry Efforts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 5pt">Charles River conducted, in good faith, a RCOI in accordance
with the Rule, followed by related and reasonable due diligence in regards to its Endosafe Products and the <I>Conflict Minerals</I> utilized
therein, which are necessary for their functionality and/or production. Our supply chain with respect to Endosafe Products is complex,
as we purchase parts and materials directly, or contract with others to manufacture parts, from many suppliers&#894; however, we do not
purchase any <I>Conflict Minerals</I> directly from any smelters, mines or refiners. In most cases, there are multiple layers of third
parties between Charles River and the ultimate upstream source of the <I>Conflict Minerals</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">We engaged Assent Compliance Inc. (Assent) to help us obtain
information, representations and certifications concerning the presence of <I>Conflict Minerals</I> in our Endosafe Products (if any),
and the sourcing thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.45pt 0pt 5pt">Specifically, we identified 86 suppliers who
provide Endosafe Product components which may contain <I>Conflict Minerals</I>. With the help of Assent, we developed and executed a
communication and inquiry program whereby each identified supplier was contacted a minimum of four times <I>via</I> phone-calls and
email communications and asked to complete a Responsible Minerals Initiative (RMI) Conflict Minerals Reporting Template (CMRT). The
CMRTs and material correspondence from our suppliers were documented and aggregated into Assent&rsquo;s survey platform, which can
(among other functions) validate whether smelters and refineries used by suppliers are recognized as compliant with the RMI
(formerly the Conflict Free Sourcing Initiative) protocol, and provide a risk assessment of the suppliers used. The following
outputs were reported:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.45pt 0pt 5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 12pt">&bull;</TD><TD STYLE="padding-right: 47.45pt">Response Rate: 78%, which represents the percentage of identified suppliers who responded to our inquiries
regarding the presence of <I>Conflict Minerals</I> in our Endosafe Products, and the sourcing thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 11.95pt">&bull;</TD><TD>The responding suppliers account for more than 75% of the components used in the Endosafe Products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 11.95pt">&bull;</TD><TD>Of the 67 responding suppliers:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.5pt"></TD><TD STYLE="width: 15.1pt">&bull;</TD><TD>6 suppliers reported no <I>Conflict Minerals</I> are present in their components sold to Charles River&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.45pt"></TD><TD STYLE="width: 15.15pt">&bull;</TD><TD STYLE="padding-right: 18.5pt">18 suppliers reported <I>Conflict Minerals</I> are present in their components sold to Charles River,
and such <I>Conflict Minerals</I> are not sourced from any <I>Covered Country </I>&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.45pt"></TD><TD STYLE="width: 15.15pt">&bull;</TD><TD STYLE="padding-right: 18.5pt">25 suppliers reported <I>Conflict Minerals</I> are present in their components sold to Charles River,
and such <I>Conflict Minerals</I> are sourced from a <I>Covered Country</I>, but such suppliers could otherwise represent they are not
supporting armed groups since they buy <I>Conflict Minerals </I>exclusively from smelters and refiners that are CFSI compliant&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.45pt"></TD><TD STYLE="width: 15.15pt">&bull;</TD><TD STYLE="padding-right: 12.05pt">12 suppliers reported <I>Conflict Minerals</I> are present in their components sold to Charles River,
and such <I>Conflict Minerals</I> are sourced from a <I>Covered Country</I>, but sourced from smelters or refiners not compliant with
CFSI&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.45pt"></TD><TD STYLE="width: 15.15pt">&bull;</TD><TD STYLE="padding-right: 5.7pt">38 suppliers could not provide sufficient detail as to whether they sourced from a <I>Covered Country</I>
and/or whether smelters or refiners in their supply chain were CFSI compliant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt"><I>Note: Suppliers sourcing more than one Conflict Mineral
for components sold to Charles River may have responded differently with regards to each Conflict Mineral sourced, and therefore any such
supplier may have been allocated to more than one output above.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.65pt 0pt 5pt">We are encouraged by the consistent engagement with our
suppliers (57% suppliers representing responsible sourcing of <I>Conflict Minerals</I>, as compared with 56% and 62% in the 2022 and 2021
reporting years, respectively). We credit this level of engagement to our internal and cross- functional Conflict Minerals Team (with
members from Compliance, Legal, Procurement and Operations), which, with the help of Assent, actively engages with our suppliers and employees
to explore solutions in sourcing <I>Conflict Minerals</I> responsibly, and raise awareness in our supply chain and among our employees
of the issues and concerns surrounding <I>Conflict Minerals</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.65pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">We have maintained our Conflict Minerals Law Statement
(available at <FONT STYLE="color: blue"><U>https://ir.criver.com/corporate-governance/highlights</U></FONT>) which outlines our commitment
to sourcing <I>Conflict Minerals </I>responsibly, and our Compliance &amp; Ethics Hotline (available at 1-866-294-3699, or <FONT STYLE="color: blue"><U>http://helpline.criver.com</U></FONT>)&#894;
and we have provided our suppliers and employees with access to Assent&rsquo;s Conflict Mineral Resource Centers where tutorials, further
education, and other resources can be found regarding <I>Conflict Minerals</I> and compliance related laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Conclusion based on Reasonable Country of Origin Inquiry</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.1pt 0pt 5pt">Despite our efforts to date, including our RCOI and related
diligence, and in consideration of the complexity of our supply chain and the Endosafe Products themselves, we could not determine that
our supply chain was not sourcing <I>Conflict Minerals</I> from one or more of the <I>Covered Countries</I>. While we believe a 77% response
rate from our suppliers is significant, we understand further improvements to our evaluation efforts and diligence practices, as well
as increased representations from our suppliers that <I>Conflict Minerals</I> are sourced responsibly, are needed to maintain, and advance
this level of engagement with our suppliers and ultimately improve upon the areas where suppliers stated the source of the <I>Conflict
Minerals</I> was either unknown or known to be non-conformant. These improvements over time will lead to a supply chain that is <I>DRC
Conflict Mineral Free</I>&#894; and therefore, we will continue to work with our partners, suppliers and supplier candidates to further
develop our evaluation efforts and diligence practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.1pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Public Conflicts Mineral Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">This information is publicly available at <FONT STYLE="color: blue"><U>www.criver.com
</U></FONT>at the SEC filings link on the investor relations page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 7.9pt; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 7.9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt; text-indent: 15.15pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.10pt 0pt 5pt; text-indent: 15.15pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">CHARLES RIVER LABORATORIES INTERNATIONAL, INC<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Matthew Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 7%">Name:</TD>
    <TD STYLE="width: 52%">Matthew Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Corporate Senior Vice President, General Counsel, Chief Compliance Officer &amp; Corporate Secretary</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Date: May 29, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Form SD</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Specialized Disclosure
Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 201.2pt 0pt 199.45pt; text-indent: 37.85pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 201.2pt 0pt 199.45pt; text-indent: 37.85pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
